ABSTRACT
INTRODUCTION
The glycosylated transmembrane protein PSMA has higher expression in prostate cancer cells compared to nonmalignant prostate tissue (1, 2) . In the last years, several PSMA-targeting radiopharmaceuticals have been developed for diagnostic or therapeutic use in prostate cancer. One of them, Ga-68 labeled PSMA-HBED-CC (PSMA-11), showed promising results in first in vivo studies (3) (4) (5) and emerged as the most frequently used PSMA-targeting tracer up to date. Currently, 68 Ga-PSMA-PET/CT offers excellent diagnosis for prostate cancer in various clinical scenarios. Although modern MRI techniques like multiparametric MRI are likely to improve the detection of clinically significant cancer, there are still conflicting results e.g. concerning the role as a prebiopsy diagnostic tool (6, 7) . With a high sensitivity and specificity of up to 70% and 100%, PSMA-PET/CT is well suited for assessing the extent of primary prostate cancer or the detection of lymph node metastases and proved to be superior to standard routine imaging (8, 9) . Even compared to 18 F-Choline-PET/CT, this modern diagnostic tool has high detection rates also in patients with low PSA values and negative choline imaging. (10) .
Although prospective, validating data is still missing, some retrospective studies reported on numerous changes in TNM stage or treatment management after 68 Ga-PSMA-PET/CT examination (11) (12) (13) . One study with 57 patients performed by Sterzing et al., observed a therapy change in 50.8% of all cases (12) .
There is a positive correlation between PSMA expression and GS. Several preclinical studies demonstrated that high PSMA expression was significantly correlated with higher GS (14, 15) . Perner et al. used tumor samples from 450 prostate cancer patients and compared PSMA expression with different clinical parameters. The authors concluded that high immunohistochemical PSMA expression in primary tumor is able to predict disease outcome independently (16). To our knowledge there is only one, larger study with robust in vivo data yet (17). Most of the published studies were based on tumor samples received from surgery or biopsy.
Therefore, the aim of this study is to evaluate differences of SUV measurements in healthy prostate tissue vs. malignant prostate lesions based on a high proportion of MRI/TRUS-fusion biopsy results in a large group of untreated patients with newly diagnosed prostate carcinoma undergoing PSMA-PET/CT. Besides, we perform correlations for SUV measurements and clinical parameters such as GS and d'Amico scale. 
PSMA-PET/CT Imaging
The synthesis of 68 Ga-PSMA-11 (median 200.5 MBq, range 92 -338) was done as described by Eder et al. (21) . 60 ± 10 minutes after intravenous injection of the tracer, PET/CT imaging was performed with a Biograph PET/CT 6 (n = 59) and mCT Flow (n = 45) scanner (Siemens, Erlangen, Germany). 
Statistical Analysis
We 
RESULTS

68
Ga-PSMA PET/CT was performed for 104 prostate cancer patients without previous local or systemic therapy. Mean SUV max of gluteal muscle was 0.60 ± 0.10 for all prostate cancer patients. Healthy prostate tissue had mean SUV max of 1.88 ± 0.44 compared to 10.77 ± 8.45 for malignant intraprostatic lesions in corresponding patients (P < 0.001; Fig. 1 ). Mean SUV max in all 104 patients was 14.47 ± 13.87. 46 patients (44.23%) showed unifocal uptake in the prostate. For 52 patients (50.00%) two or more loci with elevated SUV max were observed, for 6 men (5.77%) the exact number of foci couldn't be determined. For 65 men (62.50%), only intraprostatic tracer uptake was detected. 32.69% (n = 34) of prostate cancer patients undergoing PSMA-PET/CT were diagnosed with lymphatic metastases, 18.27% (n = 19) with bone metastases and 11.54% (n = 12) with bone and lymphatic metastases (in total 38 bone metastases in 19 patients). Lymph node metastases were located within the pelvis for 17 patients (16.35%; Table 1 ). One patient with lung metastases and one patient with a penile metastasis were diagnosed. Comparing PSMA-PET/CT with available MRI data, there was a match of detection of intraprostatic tumor lesions with highest available GS in 89.55%.
After correlation of intraprostatic, tumor-related tracer uptake with clinical parameters, a mean SUV max of 8.55 ± 5.88 was detected in patients with current PSA values of < 10 ng/ml compared to 14.97 ± 16.20 for PSA values of 10-20 ng/ml and 19.47 ± 15.47 for PSA values of more than 20 ng/ml (P < 0.001). Correlating SUV max and GS, prostate cancer lesions from biopsy with GS 6 and 7 had mean SUV max of 6.74 ± 6.10 and 11.06 ± 11.56, respectively (Fig. 2) . The highest tracer uptake was found in intraprostatic lesions with GS of 9, with a mean SUV max of 22.16 ± 18.46. Prostate cancers with high GS (8 -10) showed a statistically significant higher PSMA uptake (mean SUV max of 19.61 ± 15.44) than tumors with a GS of 6 or 7 (mean SUV max of 9.88 ± 10.49; P < 0.001). In ungrouped analyses, differences remained statistically significant for GS 6 -10 as well as for grading system according to International Society of Urological Pathologists (P < 0.001 each; Fig. 3 ). Significant differences were also observed for risk classification based on the d'Amico scale (22) : patients with high risk tumors had higher intraprostatic PSMA uptake (mean SUV max of 16.67 ± 14.88) compared to tumors with low (mean SUV max of 5.97 ± 3.69) and intermediate risk (mean SUV max of 6.98 ± 4.11) (P < 0.001; Table 2 ).
by
considering histopathological data from surgery and biopsy type (MRI/TRUS-fusion biopsy). Comparison of clinical parameters with histological results only obtained from MRI/TRUS-fusion biopsy also revealed statistically significant higher uptake in tumors with GS 8-10 than in those with GS 6-7 (mean SUV max 11.24 ± 12.9 and 19.45 ± 17.24, P = 0.004). From 28 men undergoing prostatectomy mean SUV max was 14.10 ± 11.07 (n = 15) for GS 7 tumors, compared to 20.41 ± 11.51 (n = 13) for GS 8-10 tumors (Fig. 4) . This difference of intraprostatic tracer uptake was only of borderline significance (P = 0.142; Table 3 ). The correlation of histopathological results from surgery with malignant, intraprostatic lesions obtained from 68 Ga PSMA-PET/CT leads to a calculated PET-sensitivity and specificity of 68 and 92%. For PET/CT data correlating with MRI, there was a total or near-total match of increased tracer uptake in the same prostate segments in 91%.
DISCUSSION
To our knowledge, this is the largest study evaluating the role of Ga-PSMA-PET/CT followed by radical prostatectomy (24) . In receiver operating characteristic analyses (data not shown) a SUV max cut-off of > 2.73 would lead to a sensitivity and specificity of 100% and 97.62% (95% confidence interval 91.59% to 100% and 87.43% to 99.94%) in our cohort, respectively.
These results need to be treated with caution due to the relatively small number of cases with histopathological Furthermore, we investigated the correlation of intraprostatic PSMA uptake and several clinical parameters in subgroup analysis. Among a statistically significant difference of SUV max regarding the present PSA, we also observed a significantly higher mean SUV max in tumors with higher d'Amico risk classification and GS from biopsy (P < 0.001 for grouped analyses). In consideration of a small number of patients, these differences remained statistically significant (P < 0.001 each) in ungrouped evaluation (Fig. 5) . There seems to be a strong trend of rising PSMA uptake with higher grade malignancy. To our knowledge, there is only one larger, recently published study apart from research using tissue microarrays which also described a correlation of tracer accumulation and clinical parameters: Uprimny et al. observed significantly lower PSMA uptake in tumors with GS 6 -7b and PSA < 10 ng/ml in a cohort of 90 men. The median SUV max of intraprostatic, malignant lesions was 11.5 ng/ml compared to 3.9 ng/ml in normal prostate tissue (17). This relatively high SUV max in healthy prostate tissue could be related to the fact, that for calculation of SUV max the tumor site was only verified by TRUS-guided biopsy, which has been proven insufficient (27) . In contrast MRI/TRUS-fusion biopsy comprising targeted and systematic cores-which was done for nearly 50% of the patients in our cohortleads to a precise definition of malignant and non-malignant areas in the prostate (28) . It is interesting to note, that Uprimny et al. observed a lower SUV max in GS 10 (17.7) tumors compared to GS 9 (22.8) (17) -in the same way as we did (GS 10: 18.3; GS 9: 22.2) -assuming that lower, intraprostatic tracer uptake is caused by dedifferentiation of tumor cells in GS 10 prostate carcinomas.
Another analysis performed by Fendler et al. observed a significantly lower SUV max in histopathologypositive segments with GS of 6 compared to segments with GS of 7 or more with a P value of 0.012. However, no statistically significant difference was reported for segments with a GS of 7 or more (23) . The relatively small-sized cohort (n = 21) and the small number of patients with a high GS (GS 8: 3 men; GS 9: 7 men) might explain the lack of difference compared to our findings.
Especially for definitive radiotherapy, identification of high malignant intraprostatic cancer segments is extremely helpful, because of the high risk for local recurrence of these so called "dominant intraprostatic tumor lesions" after local treatment (29, 30) . The concept of treating dominant intraprostatic tumor lesions with an increased dose (boost) to improve local control is objective of a currently recruiting randomized phase III trial (FLAME-trial) that is, however, based on MRI-guided definition of dominant intraprostatic tumor lesions (31) . It has recently been shown, that delineation of target volume and dominant intraprostatic tumor lesions is also feasible with PSMA-PET/CT (32) . Due to some benefits of PET scan compared to MRI scans, irradiation planning based on PSMA-PET/CT would be of great interest (Fig. 6 ).
The major limitations of our study are its retrospective nature and the small number of histopathological results from prostatectomy. Most patients underwent radiotherapy or androgen deprivation after PSMA-PET/CT, why validated, histopathological data from surgery is only available for 26.92%. Besides, for clinical correlation (e.g. high GS) only a few patients could be included in our analyses. On the other hand, our study is one of the largest evaluating the role of PSMA-PET/CT for intraprostatic tumor detection and correlation of SUV max with Gleason score and risk classification. Hence, our data can be used as a basis for further, prospective studies.
CONCLUSION
Our study confirms that PSMA-PET/CT is an excellent diagnostic tool for the detection of intraprostatic tumor lesions. As one of the first analyses in a large patient cohort our results indicate a correlation of tracer uptake with GS and d'Amico risk classification. This information might be very useful for further diagnostic procedures i.e. biopsy-guidance and treatment planning in radiation oncology. 
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